Morpholine → 6-[3,5-Bis(trifluoromethyl)benzyl]-5,6,7,8,9,10-hexahydro-4-(2-methylphenyl)-2-(morpholine-4-yl)-5-oxopyrimido[4,5-b][1,5]diazocine

HRID 1829653Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1829653
[F:1][C:2]([F:39])([F:38])[C:3]1[CH:4]=[C:5]([CH:31]=[C:32]([C:34]([F:37])([F:36])[F:35])[CH:33]=1)[CH2:6][N:7]1[CH2:14][CH2:13][CH2:12][NH:11][C:10]2[N:15]=[C:16](S(C)(=O)=O)[N:17]=[C:18]([C:19]3[CH:24]=[CH:23][CH:22]=[CH:21][C:20]=3[CH3:25])[C:9]=2[C:8]1=[O:30].[NH:40]1[CH2:45][CH2:44][O:43][CH2:42][CH2:41]1>>[F:1][C:2]([F:39])([F:38])[C:3]1[CH:4]=[C:5]([CH:31]=[C:32]([C:34]([F:37])([F:36])[F:35])[CH:33]=1)[CH2:6][N:7]1[CH2:14][CH2:13][CH2:12][NH:11][C:10]2[N:15]=[C:16]([N:40]3[CH2:45][CH2:44][O:43][CH2:42][CH2:41]3)[N:17]=[C:18]([C:19]3[CH:24]=[CH:23][CH:22]=[CH:21][C:20]=3[CH3:25])[C:9]=2[C:8]1=[O:30]

Komponenten

3

Edukt 2

HCID 8083MorpholineHCID 220535916-[3,5-Bis(trifluoromethyl)benzyl]-5,6,7,8,9,10-hexahydro-4-(2-methylphenyl)-2-(methylsulfonyl)-5-oxopyrimido[4,5-b][1,5]diazocine

Produkt 1

HCID 220535736-[3,5-Bis(trifluoromethyl)benzyl]-5,6,7,8,9,10-hexahydro-4-(2-methylphenyl)-2-(morpholine-4-yl)-5-oxopyrimido[4,5-b][1,5]diazocineAusbeute 101 %

Versuchsvorschrift

In a similar manner to Example 1, 6-[3,5-bis(trifluoromethyl)benzyl]-5,6,7,8,9,10-hexahydro-4-(2-methylphenyl)-2-(methylsulfonyl)-5-oxopyrimido[4,5-b][1,5]diazocine (Compound of Reference Example 19; 85.9 mg) was reacted with morpholine (15.7 mg) to obtain 6-[3,5-bis(trifluoromethyl)benzyl]-5,6,7,8,9,10-hexahydro-4-(2-methylphenyl)-2-(morpholine-4-yl)-5-oxopyrimido[4,5-b][1,5]diazocine (87.8 mg, 100%).

Quellen und Nachweise

ORD-Eintrag
ord-f03ddd4de2ed4156b762a064f11ec5a3
Quelldatensatz
uspto-grants-2006_06
Patentnummer
US07064119B2

Notizen zur Reaktion

Wird geladen…